Title |
Abundance of Flt3 and its ligand in astrocytic tumors
|
---|---|
Published in |
OncoTargets and therapy, May 2013
|
DOI | 10.2147/ott.s43114 |
Pubmed ID | |
Authors |
C Eßbach, N Andrae, D Pachow, J-P Warnke, A Wilisch-Neumann, E Kirches, C Mawrin |
Abstract |
Molecular targeted therapies for astrocytic tumors are the subject of growing research interest, due to the limited response of these tumors, especially glioblastoma multiforme, to conventional chemotherapeutic regimens. Several of these approaches exploit the inhibition of receptor tyrosine kinases. To date, it has not been elucidated if fms-like tyrosine kinase-3 (Flt3) and its natural ligand (Flt3L) are expressed in astrocytic tumors, although some of the clinically intended small-molecule receptor tyrosine kinase inhibitors affect Flt3, while others do not. More importantly, the recent proof of principle for successful stimulation of the immune system against gliomas in preclinical models via local Flt3L application requires elucidation of this receptor tyrosine kinase pathway in these tumors in more detail. This therapy is based on recruitment of Flt3-positive dendritic cells, but may be corroborated by activity of this signaling pathway in glioma cells. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 16 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Doctoral Student | 3 | 19% |
Student > Bachelor | 3 | 19% |
Student > Ph. D. Student | 3 | 19% |
Professor | 2 | 13% |
Student > Master | 2 | 13% |
Other | 2 | 13% |
Unknown | 1 | 6% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 6 | 38% |
Biochemistry, Genetics and Molecular Biology | 5 | 31% |
Agricultural and Biological Sciences | 2 | 13% |
Social Sciences | 1 | 6% |
Neuroscience | 1 | 6% |
Other | 0 | 0% |
Unknown | 1 | 6% |